Biotech Stocks To Buy Based on Artificial Intelligence: Returns up to 10.72% in 3 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Short
Forecast Length: 3 Days (10/19/2018 - 10/22/2018)
I Know First Average: 3.56%

Read The Full Forecast

Biotech Stocks To Buy

Biotech Stocks To Watch Based on Big Data Analytics: Returns up to 50.60% in 14 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 14 Days (09/18/2018 - 10/03/2018)
I Know First Average: 8.80%

Read The Full Forecast

Biotech Stocks To Watch

Biotech Stocks To Buy Based on Predictive Analytics : Returns up to 45.65% in 14 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 14 Days (09/18/2018 - 10/02/2018)
I Know First Average: 7.76%

Read The Full Forecast

Biotech Stocks To Buy

Biotechnology Stocks To Watch Based on Stock Algorithm: Returns up to 49.78% in 14 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 14 Days (09/17/2018 - 10/01/2018)
I Know First Average: 16.21%

Read The Full Forecast

Biotechnology Stocks To Watch

Biotech Stocks To Buy Based on Stock Prediction Algorithm: Returns up to 49.57% in 14 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 14 Days (09/16/2018 - 09/30/2018)
I Know First Average: 15.91%

Read The Full Forecast

Biotech Stocks To Buy

Biotechnology Stocks To Buy Based on Deep Learning: Returns up to 52.38% in 7 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 7 Days (09/18/2018 - 09/25/2018)
I Know First Average: 15.69%

Read The Full Forecast

Biotechnology Stocks To Watch

Winning Stock Forecast: Acadia, Protalix Bring Big Returns In The BioTech Space

ACAD Winning Stock Forecast

By Pöllö -commons.wikimedia.org

This week ACAD saw a 52.38% jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. Before this week, ACAD’s shares have been under pressure from what turned out to be an inaccurate report from CNN. Acadia Pharmaceuticals is again bringing in impressive returns. The drug under fire was Nuplazid. The FDA only recently discarded these allegations to be untrue. Nuplazid made up $57.1 million in sales Q2 for ACAD, an 18% increase from the first quarter. Sales of the drug are increasing 87% year over year. The

Read More

Pages:1234567...22»